image
Healthcare - Medical - Devices - NASDAQ - US
$ 4.75
6.26 %
$ 2.95 M
Market Cap
-0.24
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TIVC stock under the worst case scenario is HIDDEN Compared to the current market price of 4.75 USD, Tivic Health Systems, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TIVC stock under the base case scenario is HIDDEN Compared to the current market price of 4.75 USD, Tivic Health Systems, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one TIVC stock under the best case scenario is HIDDEN Compared to the current market price of 4.75 USD, Tivic Health Systems, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TIVC

image
$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.0$6.0$6.0$4.0$4.0$2.0$2.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
780 K REVENUE
-33.67%
-5.66 M OPERATING INCOME
31.34%
-5.66 M NET INCOME
31.40%
-5.72 M OPERATING CASH FLOW
32.73%
0 INVESTING CASH FLOW
100.00%
4.33 M FINANCING CASH FLOW
-49.08%
180 K REVENUE
42.86%
-1.54 M OPERATING INCOME
-7.83%
-1.48 M NET INCOME
-3.21%
-1.36 M OPERATING CASH FLOW
2.99%
0 INVESTING CASH FLOW
0.00%
1.18 M FINANCING CASH FLOW
1314.43%
Balance Sheet Tivic Health Systems, Inc.
image
Current Assets 2.64 M
Cash & Short-Term Investments 2 M
Receivables 69 K
Other Current Assets 568 K
Non-Current Assets 168 K
Long-Term Investments 0
PP&E 119 K
Other Non-Current Assets 49 K
71.32 %20.24 %4.24 %Total Assets$2.8m
Current Liabilities 272 K
Accounts Payable 125 K
Short-Term Debt 0
Other Current Liabilities 147 K
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
45.96 %54.04 %Total Liabilities$272.0k
EFFICIENCY
Earnings Waterfall Tivic Health Systems, Inc.
image
Revenue 780 K
Cost Of Revenue 778 K
Gross Profit 2 K
Operating Expenses 5.66 M
Operating Income -5.66 M
Other Expenses -6 K
Net Income -5.66 M
1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)780k(778k)2k(6m)(6m)6k(6m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.26% GROSS MARGIN
0.26%
-725.77% OPERATING MARGIN
-725.77%
-725.00% NET MARGIN
-725.00%
-223.08% ROE
-223.08%
-201.46% ROA
-201.46%
-223.31% ROIC
-223.31%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tivic Health Systems, Inc.
image
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)(9m)(9m)202020202021202120222022202320232024202420252025
Net Income -5.66 M
Depreciation & Amortization 352 K
Capital Expenditures 0
Stock-Based Compensation 229 K
Change in Working Capital -1 M
Others -251 K
Free Cash Flow -5.72 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tivic Health Systems, Inc.
image
TIVC has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Tivic Health Systems, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call Transcript Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q4 2024 Results Conference Call March 21, 2025 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Lisa Wolf - Interim Chief Financial Officer Operator Welcome to Tivic Health Systems Year-End 2024 Financial Results and Operational Update Conference Call. This call has been prerecorded and the questions you have submitted in advance will be answered following prepared remarks. seekingalpha.com - 1 month ago
Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company's operations. “The important strategic events of the past several months have been nothing short of transformative,” stated Tivic Health Chief Executive Officer, Jennifer Ernst. “We have successfully reshaped the. businesswire.com - 1 month ago
Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID. businesswire.com - 1 month ago
Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today new data that shows personalizing its non-invasive vagus nerve stimulation (ncVNS) method optimized the stimulation's impact on autonomic nervous system activity. Tivic Health believes these findings strongly support its strategy to develop highly personalized neuromodulation devices that can better address inflammatory, cardiac and neurologic disorders compared to c. businesswire.com - 1 month ago
Tivic Health Systems, Inc. Announces Reverse Stock Split FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC) (“Tivic Health” or the “Company), a diversified therapeutics company, announced today that its Board of Directors has declared a 1-for-17 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (“Nasdaq”), and is part of the. businesswire.com - 1 month ago
Tivic Health Files Patent For Optimized Electrical Stimulation of the Vagus Nerve FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, announced today that it has filed a new patent application with the U.S. Patent Office. Patent No. 63,492,402, entitled “Method and Apparatus for Electrical Stimulation of the Vagus Nerve,” expands the claims and protection around the technology in advance of potential U.S. Food &amp. businesswire.com - 1 month ago
Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement estab. businesswire.com - 2 months ago
CEO Letter to Shareholders Issued by Tivic Health FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, today released its annual CEO letter to shareholders. Dear Fellow Shareholders: As we conclude 2024 and look forward to 2025, I'd like to take this opportunity to recap some of the important developments this year and share some of our expectations for 2025. Improvements in Commercial Business: We launched ClearUP 2.0, resulting in improved c. businesswire.com - 3 months ago
Tivic Reports Third Quarter 2024 Financial Results and Provides Business Update FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced third quarter and nine-months ended September, 30, 2024 financial results and discussed growth strategies based on its novel, patent-pending vagus nerve stimulation (VNS) science and device technology. “This quarter we made significant progress on each of the three prongs of our strategy for delivering shareholder value," st. businesswire.com - 5 months ago
Tivic Health Systems, Inc. (TIVC) Q3 2024 Earnings Call Transcript Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Operator Welcome to Tivic Health Systems' Third Quarter 2024 Financial Results and Operational Update Conference Call. This call has been pre-recorded and questions you have submitted in advance will be answered following the prepared remarks. seekingalpha.com - 5 months ago
Enrollment Complete in Tivic Health Optimization Study for its Non-Invasive Vagus Nerve Stimulation Device FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health's patent pending, non-invasive vagus nerve stimulation (VNS) device. The study is being conducted by The Feinstein Institute of Bioelectronic Medicine. The objective of the study is to identify device parameters that optimally influence autonomi. businesswire.com - 5 months ago
Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14 FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced it will report financial results on Thursday, November 14 after market close. The release will be followed by a pre-recorded conference call and webcast at 1:30 p.m. PST / 4:30 p.m. EST. Shareholders, interested parties, and prospective investors are invited to join via dial in or webcast. The company invites questions to be. businesswire.com - 5 months ago
8. Profile Summary

Tivic Health Systems, Inc. TIVC

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 2.95 M
Dividend Yield 0.00%
Description Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Contact 25821 Industrial Boulevard, Hayward, CA, 94545 https://www.tivichealth.com
IPO Date Nov. 11, 2021
Employees 7
Officers Ms. Lisa G. Wolf Interim Chief Financial Officer Dr. Blake Gurfein Ph.D. Chief Scientific Officer Ms. Jennifer Ernst Co-Founder, Chief Executive Officer & Director Mr. Michael Kevin Handley Chief Operating Officer & President of Tivic Biopharma